<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Disopyramide</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Disopyramide">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Disopyramide</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Disopyramide</b> (INN, trade names <b>Norpace</b> and <b>Rythmodan</b>) is an antiarrhythmic medication used in the treatment of ventricular tachycardia.<span class="mw-ref" id="cite_ref-1"><a href="#cite_note-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent.<span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-pmid2285495_3-0"><a href="#cite_note-pmid2285495-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility.<span class="mw-ref" id="cite_ref-pmid474380_4-0"><a href="#cite_note-pmid474380-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-pmid4150336_5-0"><a href="#cite_note-pmid4150336-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Disopyramide also has an anticholinergic effect on the heart which accounts for many adverse side effects. Disopyramide is available in both oral and intravenous forms, and has a low degree of toxicity.<span class="mw-ref" id="cite_ref-pmid4150336_5-1"><a href="#cite_note-pmid4150336-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Disopyramide</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Disopyramide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Disopyramide.svg.png" data-file-width="512" data-file-height="463" data-file-type="drawing" height="199" width="220"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Disopramide.png" tppabs="https://ptable.com/wiki/compounds/I/m/Disopramide.png" data-file-width="806" data-file-height="709" data-file-type="bitmap" height="194" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Norpace</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/disopyramide-phosphate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/disopyramide-phosphate.html'" tppabs="https://www.drugs.com/monograph/disopyramide-phosphate.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a682408.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a682408.html'" tppabs="https://medlineplus.gov/druginfo/meds/a682408.html" class="external text external">a682408</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B2<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Oral, intravenous</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>C01BA03<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=C01BA03  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=C01BA03'" tppabs="https://www.whocc.no/atc_ddd_index/?code=C01BA03" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>High</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>50% to 65%<br>(concentration-dependent)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Hepatic (CYP3A4-mediated)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>6.7 hours (range 4 to 10 hours)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Renal (80%)</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(<i>RS</i>)-4-(Diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=3737-09-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=3737-09-5'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=3737-09-5" class="external text external">3737-09-5</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/3114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/3114'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/3114" class="external text external">3114</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7167  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7167'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7167" class="external text external">7167</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00280'" tppabs="https://www.drugbank.ca/drugs/DB00280" class="external text external">DB00280</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.3002.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.3002.html'" tppabs="http://www.chemspider.com/Chemical-Structure.3002.html" class="external text external">3002</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=GFO928U8MQ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=GFO928U8MQ'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=GFO928U8MQ" class="external text external">GFO928U8MQ</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00303  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00303'" tppabs="https://www.kegg.jp/entry/D00303" class="external text external">D00303</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4657  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4657'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4657" class="external text external">CHEBI:4657</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL517  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL517'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL517" class="external text external">ChEMBL517</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID1045536  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID1045536'" tppabs="https://comptox.epa.gov/dashboard/DTXSID1045536" class="external text external">DTXSID1045536</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.021.010  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.021.010'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.021.010" class="external text external">100.021.010</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>21</sub><span>H</span><sub>29</sub><span>N</span><sub>3</sub><span>O</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">339.483</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%29C%28c1ncccc1%29%28c2ccccc2%29CCN%28C%28C%29C%29C%28C%29C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%29C%28c1ncccc1%29%28c2ccccc2%29CCN%28C%28C%29C%29C%28C%29C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%29C%28c1ncccc1%29%28c2ccccc2%29CCN%28C%28C%29C%29C%28C%29C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Melting point</th><td>94.5 to 95<span>&nbsp;</span>°C (202.1 to 203.0<span>&nbsp;</span>°F)</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C(N)C(c1ncccc1)(c2ccccc2)CCN(C(C)C)C(C)C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:UVTNFZQICZKOEM-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477166575&page2=Disopyramide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477166575&page2=Disopyramide'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477166575&page2=Disopyramide" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Disopyramide's Class 1a activity is similar to that of <a href="Quinidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinidine" title="Quinidine">quinidine</a> in that it targets sodium channels to inhibit conduction.<span class="mw-ref" id="cite_ref-pmid2285495_3-1"><a href="#cite_note-pmid2285495-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid4150336_5-2"><a href="#cite_note-pmid4150336-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Disopyramide depresses the increase in sodium permeability of the cardiac myocyte during Phase 0 of the cardiac action potential, in turn decreasing the inward sodium current. This results in an increased threshold for excitation and a decreased upstroke velocity.<span class="mw-ref" id="cite_ref-pmid2285495_3-2"><a href="#cite_note-pmid2285495-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Disopyramide prolongs the PR interval by lengthening both the QRS and P wave duration.<span class="mw-ref" id="cite_ref-pmid4150336_5-3"><a href="#cite_note-pmid4150336-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> This effect is particularly well suited in the treatment of ventricular tachycardia as it slows the action potential propagation through the atria to the ventricles. Disopyramide does not act as a blocking agent for beta or alpha adrenergic receptors, but does have a significant negative inotropic effect on the ventricular myocardium.<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> As a result, the use of disopyramide may reduce contractile force up to 42% at low doses and up to 100% in higher doses leading to heart failure.<span class="mw-ref" id="cite_ref-pmid4150336_5-4"><a href="#cite_note-pmid4150336-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>

<p>Levites proposed a possible secondary mode of action for disopyramide, against reentrant arrhythmias after an ischemic insult. Disopyramide decreases the inhomogeneity between infarcted and normal myocardium refractory periods; in addition to lengthening the refractory period.<span class="mw-ref" id="cite_ref-pmid474380_4-1"><a href="#cite_note-pmid474380-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> This decreases the chance of re-entry depolarization, because signals are more likely to encounter tissue in a refractory state which cannot be excited.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> This provides a possible treatment for atrial and ventricular fibrillation, as it restores pacemaker control of the tissue to the SA and AV nodes.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Obstructive_hypertrophic_cardiomyopathy">Obstructive hypertrophic cardiomyopathy</h2></summary>
    
<p>Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, occurring in 1:500 individuals in the general population. It is estimated that there are 600,000 individuals in the United States with hypertrophic cardiomyopathy. The most common variant of HCM presents with left ventricular (LV) intracavitary obstruction due to systolic anterior motion of the mitral valve, and mitral-septal contact, diagnosed readily with echocardiography. Pharmacologic treatment with negative inotropic drugs is first-line therapy. Beta-blockers are used first, and while they improve symptoms of shortness of breath, chest pain and exercise intolerance, they do not reduce resting LV intraventricular pressure gradients and often are inadequate to control symptoms. Many investigators and clinicians believe that disopyramide controlled release is the most potent agent available for reducing resting pressure gradients and improving symptoms.<span class="mw-ref" id="cite_ref-ReferenceA_9-0"><a href="#cite_note-ReferenceA-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-ReferenceB_10-0"><a href="#cite_note-ReferenceB-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-pmid23704138_12-0"><a href="#cite_note-pmid23704138-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Disopyramide has been actively used for more than 30 years.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> Disopyramide administration for obstructive HCM has a IIa recommendation in the 2011 American Heart Association/American College of Cardiology Foundation guidelines for treatment of obstructive HCM.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> A IIa treatment recommendation indicates that benefits outweigh risk, and that it is reasonable to administer treatment.</p>

<p>Negative inotropes improve LV obstruction by decreasing LV ejection acceleration and hydrodynamic forces on the mitral valve. Disopyramide's particular efficacy is due to its potent negative inotropic effects; in head-to-head comparison, it is more effective for gradient reduction than either beta-blocker or verapamil.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Disopyramide is most often administered with beta-blockade. When used in patients resistant to beta-blockade, disopyramide is effective in 60% of cases, reducing symptoms and gradient to the extent that invasive procedures such as surgical septal myectomy are not required.<span class="mw-ref" id="cite_ref-pmid23704138_12-1"><a href="#cite_note-pmid23704138-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>Disopyramide, despite its efficacy, has one main side effect that has limited its use in the US, though it has seen wider application in Canada, UK and Japan. Vagal blockade predictably causes dry mouth, and in men with prostatism, may cause urinary retention. Teichman et al. showed that <a href="Pyridostigmine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyridostigmine" title="Pyridostigmine">pyridostigmine</a> used in combination with disopyramide substantially alleviates vagolytic side effects without compromising antiarrhythmic efficacy.<span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> This combination has also been shown to be effective and safe in obstructive HCM in a large cohort of patients.<span class="mw-ref" id="cite_ref-pmid23704138_12-2"><a href="#cite_note-pmid23704138-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Some clinicians prescribe pyridostigmine sustained release (marketed in the US as Mestinon Timespan) to every patient begun on disopyramide.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> This combination increases acceptance of higher disopyramide dosing, important since there is a dose-response correlation in obstructive HCM, higher doses yielding lower gradients.</p>

<p>Another concern about disopyramide has been the hypothetical potential for inducing sudden death from its type 1 anti-arrhythmic effects. However, a multicenter registry and two recent cohort registries have largely reduced this concern, by showing sudden death rates lower than that observed from the disease itself.<span class="mw-ref" id="cite_ref-ReferenceA_9-1"><a href="#cite_note-ReferenceA-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-ReferenceB_10-1"><a href="#cite_note-ReferenceB-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-pmid23704138_12-3"><a href="#cite_note-pmid23704138-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>These concerns about the drug must be viewed from the clinical perspective that disopyramide is generally the last agent that is tried for patients before they are referred for invasive septal reduction with surgical septal myectomy (an open-heart operation) or alcohol septal ablation (a controlled heart attack). Both of these invasive procedures have risk of morbidity and mortality.</p>

<p>For selected patients, a trial of oral disopyramide is a reasonable approach before proceeding to invasive septal reduction. Patients who respond to disopyramide are continued on the drug. Those who continue to have disabling symptoms or who experience side effects are promptly referred for septal reduction. Using such a stepped strategy, investigators have reported that survival does not differ from that observed in the age-matched normal United States population.<span class="mw-ref" id="cite_ref-pmid23704138_12-4"><a href="#cite_note-pmid23704138-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Cardiac_adverse_effects">Cardiac adverse effects</h2></summary>
    
<ul><li>Acute heart failure – Disopyramide should not be given to patients with impaired LV systolic function and low ejection fraction. Heart failure is not seen when disopyramide is used in patients with normal or supernormal LV systolic function.</li>
<li>Severe hypotension – Disopyramide should not be given to patients with impaired LV systolic function and low ejection fraction. Hypotension is not seen in patients with normal or supernormal LV systolic function.</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Extracardiac_effects">Extracardiac effects</h2></summary>
    
<p><a href="Atropine.htm" tppabs="https://ptable.com/wiki/compounds/A/Atropine" title="Atropine">Atropine</a> like effects (anticholinergic)<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>
<ul><li>Dry mouth</li>
<li>Constipation</li>
<li>Urinary retention – Disopyramide should not be given to patients with symptomatic prostatism.</li>
<li>Blurred vision</li>
<li>Glaucoma</li>
<li>Rash</li>
<li>Agranulocytosis</li></ul>

<p>Additionally, disopyramide may enhance the hypoglycaemic effect of <a href="Gliclazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Gliclazide" title="Gliclazide">gliclazide</a>, <a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">insulin</a>, and <a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Metformin" title="Metformin">metformin</a>.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Actisomide</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-1"> <span id="mw-reference-text-cite_note-1" class="mw-reference-text"><cite id="CITEREFGuyton,_Arthur_C.Hall,_John_E.2006" class="citation book cs1">Guyton, Arthur C.; Hall, John E. (2006). <i>Textbook of Medical Physiology</i> (11th ed.). Philadelphia: Elsevier Saunders.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite id="CITEREFRizosBrachmannLengfelderSchmitt1987" class="citation journal cs1">Rizos, I; Brachmann, J; Lengfelder, W; Schmitt, C; von Olshausen, K; Kübler, W; Senges, J (1987). "Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: Intraindividual comparison in patients with sustained ventricular tachycardia". <i>European Heart Journal</i>. <b>8</b> (2): 154–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Foxfordjournals.eurheartj.a062243  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Foxfordjournals.eurheartj.a062243'" tppabs="https://doi.org/10.1093%2Foxfordjournals.eurheartj.a062243" class="external text external">10.1093/oxfordjournals.eurheartj.a062243</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3569310  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3569310'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3569310" class="external text external">3569310</a>.</cite></span></li><li id="cite_note-pmid2285495-3"> <span id="mw-reference-text-cite_note-pmid2285495-3" class="mw-reference-text"><cite id="CITEREFKimBenowitz1990" class="citation journal cs1">Kim, S. Y.; Benowitz, N. L. (1990). "Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide". <i>Drug Safety</i>. <b>5</b> (6): 393–420. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00002018-199005060-00002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00002018-199005060-00002'" tppabs="https://doi.org/10.2165%2F00002018-199005060-00002" class="external text external">10.2165/00002018-199005060-00002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2285495  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2285495'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2285495" class="external text external">2285495</a>.</cite></span></li><li id="cite_note-pmid474380-4"> <span id="mw-reference-text-cite_note-pmid474380-4" class="mw-reference-text"><cite id="CITEREFLevitesAnderson1979" class="citation journal cs1">Levites, R; Anderson, G. J. (1979). "Electrophysiological effects of disopyramide phosphate during experimental myocardial ischemia". <i>American Heart Journal</i>. <b>98</b> (3): 339–44. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0002-8703%2879%2990046-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0002-8703%2879%2990046-2'" tppabs="https://doi.org/10.1016%2F0002-8703%2879%2990046-2" class="external text external">10.1016/0002-8703(79)90046-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/474380  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/474380'" tppabs="https://pubmed.ncbi.nlm.nih.gov/474380" class="external text external">474380</a>.</cite></span></li><li id="cite_note-pmid4150336-5"> <span id="mw-reference-text-cite_note-pmid4150336-5" class="mw-reference-text"><cite id="CITEREFMathur1972" class="citation journal cs1">Mathur, P. P. (1972). "Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate". <i>American Heart Journal</i>. <b>84</b> (6): 764–70. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0002-8703%2872%2990069-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0002-8703%2872%2990069-5'" tppabs="https://doi.org/10.1016%2F0002-8703%2872%2990069-5" class="external text external">10.1016/0002-8703(72)90069-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4150336  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4150336'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4150336" class="external text external">4150336</a>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text">Hulting J, Rosenhamer G: Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. Acta Med Scand 199:41-51, 1976.</span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text">Guyton, Arthur C., Hall, John E. (2006). Textbook of Medical Physiology (11th ed.). Philadelphia: Elsevier Saunders.</span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text">Katzung, Bertram G., Masters, Susan B., Trevor, Anthony J. (2009). Basic and Clinical Pharmacology (11th ed.). New York: McGraw Hill</span></li><li id="cite_note-ReferenceA-9"> <span id="mw-reference-text-cite_note-ReferenceA-9" class="mw-reference-text"><cite id="CITEREFBallIvanovRakowskiWigle2011" class="citation journal cs1">Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, Williams WG, Schwartz L, Guttman A, Woo A (2011). "Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment". <i>J Am Coll Cardiol</i>. <b>58</b>: 2313–2321. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jacc.2011.08.040  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jacc.2011.08.040'" tppabs="https://doi.org/10.1016%2Fj.jacc.2011.08.040" class="external text external">10.1016/j.jacc.2011.08.040</a>.</cite></span></li><li id="cite_note-ReferenceB-10"> <span id="mw-reference-text-cite_note-ReferenceB-10" class="mw-reference-text"><cite id="CITEREFSherridBaracMcKennaElliott2005" class="citation journal cs1">Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ (2005). "Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy". <i>J Am Coll Cardiol</i>. <b>45</b> (8): 1251–1258. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jacc.2005.01.012  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jacc.2005.01.012'" tppabs="https://doi.org/10.1016%2Fj.jacc.2005.01.012" class="external text external">10.1016/j.jacc.2005.01.012</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15837258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15837258'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15837258" class="external text external">15837258</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite id="CITEREFElliottGimenoThamanShah2006" class="citation journal cs1">Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ (2006). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860645  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860645'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860645" class="external text external">"Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy"</a>. <i>Heart</i>. <b>92</b> (6): 785–791. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fhrt.2005.068577  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fhrt.2005.068577'" tppabs="https://doi.org/10.1136%2Fhrt.2005.068577" class="external text external">10.1136/hrt.2005.068577</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860645  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860645'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860645" class="external text external">1860645</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16216855  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16216855'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16216855" class="external text external">16216855</a>.</cite></span></li><li id="cite_note-pmid23704138-12"> <span id="mw-reference-text-cite_note-pmid23704138-12" class="mw-reference-text"><cite id="CITEREFSherridShettyWinsonKim2013" class="citation journal cs1">Sherrid, M. V.; Shetty, A; Winson, G; Kim, B; Musat, D; Alviar, C. L.; Homel, P; Balaram, S. K.; Swistel, D. G. (2013). <a href="javascript:if(confirm('https://doi.org/10.1161/CIRCHEARTFAILURE.112.000122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161/CIRCHEARTFAILURE.112.000122'" tppabs="https://doi.org/10.1161/CIRCHEARTFAILURE.112.000122" class="external text external">"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil"</a>. <i>Circulation: Heart Failure</i>. <b>6</b> (4): 694–702. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1161%2FCIRCHEARTFAILURE.112.000122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161%2FCIRCHEARTFAILURE.112.000122'" tppabs="https://doi.org/10.1161%2FCIRCHEARTFAILURE.112.000122" class="external text external">10.1161/CIRCHEARTFAILURE.112.000122</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23704138  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23704138'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23704138" class="external text external">23704138</a>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFPollick_C1982" class="citation journal cs1">Pollick C (1982). "Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide". <i>N Engl J Med</i>. <b>307</b> (16): 997–999. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2Fnejm198210143071607  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2Fnejm198210143071607'" tppabs="https://doi.org/10.1056%2Fnejm198210143071607" class="external text external">10.1056/nejm198210143071607</a>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFGershMaronBonowDearani2011" class="citation journal cs1">Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011). "accf/aha guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". <i>J Am Coll Cardiol</i>. <b>58</b> (25): e212–260. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jacc.2011.06.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jacc.2011.06.011'" tppabs="https://doi.org/10.1016%2Fj.jacc.2011.06.011" class="external text external">10.1016/j.jacc.2011.06.011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22075469  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22075469'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22075469" class="external text external">22075469</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text">Kajimoto K, Imai T, Minami Y, Kasanuki H. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol. 2010;106:1307-1312</span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite id="CITEREFTeichmanFerrickKimMatos1987" class="citation journal cs1">Teichman SL, Ferrick A, Kim SG, Matos JA, Waspe LE, Fisher JD (1987). "Disopyramide-pyridostigmine interaction: Selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect". <i>J Am Coll Cardiol</i>. <b>10</b> (3): 633–641. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0735-1097%2887%2980207-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0735-1097%2887%2980207-3'" tppabs="https://doi.org/10.1016%2Fs0735-1097%2887%2980207-3" class="external text external">10.1016/s0735-1097(87)80207-3</a>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text">Sherrid MV, Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54:483-492</span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text">Rang and Dale's pharmacology</span></li></ol></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><a href="javascript:if(confirm('https://web.archive.org/web/20061022203317/http://www.rxlist.com/cgi/generic2/disopyr_cp.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20061022203317/http://www.rxlist.com/cgi/generic2/disopyr_cp.htm'" tppabs="https://web.archive.org/web/20061022203317/http://www.rxlist.com/cgi/generic2/disopyr_cp.htm" class="external text external">Disopyramide on RxList</a></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Antiarrhythmic_agents_(C01B)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antiarrhythmic_agents_(C01B)" style="font-size:114%;margin:0 4em">Antiarrhythmic agents (C01B)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Channel blockers</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="class_I(Na+_channel_blockers)" scope="row" class="navbox-group" style="width:1%">class I<br>(Na<sup>+</sup> channel blockers)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">class Ia (Phase 0→ and Phase 3→)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Ajmaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Ajmaline" title="Ajmaline">Ajmaline</a></li>
<li><a href="Disopyramide.htm" tppabs="https://ptable.com/wiki/compounds/A/Disopyramide" title="Disopyramide">Disopyramide</a></li>
<li><a href="Dihydroquinidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydroquinidine" title="Dihydroquinidine">Hydroquinidine</a></li>
<li>Lorajmine</li>
<li>Prajmaline</li>
<li><a href="Procainamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Procainamide" title="Procainamide">Procainamide</a><sup>#</sup></li>
<li><a href="Quinidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinidine" title="Quinidine">Quinidine</a><sup>#</sup></li>
<li>Sparteine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">class Ib (Phase 3←)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>IV</i>
<ul><li><a href="Lidocaine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lidocaine" title="Lidocaine">Lidocaine</a><sup>#</sup></li></ul></li>
<li><i>enteral</i>
<ul><li><a href="Aprindine.htm" tppabs="https://ptable.com/wiki/compounds/A/Aprindine" title="Aprindine">Aprindine</a></li>
<li><a href="Mexiletine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mexiletine" title="Mexiletine">Mexiletine</a></li>
<li><a href="Tocainide.htm" tppabs="https://ptable.com/wiki/compounds/A/Tocainide" title="Tocainide">Tocainide</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">class Ic (Phase 0→)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Encainide.htm" tppabs="https://ptable.com/wiki/compounds/A/Encainide" title="Encainide">Encainide</a><sup>‡</sup></li>
<li>Ethacizine</li>
<li><a href="Flecainide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flecainide" title="Flecainide">Flecainide</a></li>
<li><a href="Indecainide.htm" tppabs="https://ptable.com/wiki/compounds/A/Indecainide" title="Indecainide">Indecainide</a><sup>‡</sup></li>
<li>Lorcainide</li>
<li><a href="Moracizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Moracizine" title="Moracizine">Moracizine</a><sup>‡</sup></li>
<li><a href="Propafenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Propafenone" title="Propafenone">Propafenone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">class III<br>(Phase 3→, K<sup>+</sup> channel blockers)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amiodarone.htm" tppabs="https://ptable.com/wiki/compounds/A/Amiodarone" title="Amiodarone">Amiodarone</a></li>
<li><a href="Bretylium.htm" tppabs="https://ptable.com/wiki/compounds/A/Bretylium" title="Bretylium">Bretylium</a></li>
<li>Bunaftine</li>
<li>Celivarone<sup>†</sup></li>
<li><a href="Dofetilide.htm" tppabs="https://ptable.com/wiki/compounds/A/Dofetilide" title="Dofetilide">Dofetilide</a></li>
<li>Dronedarone</li>
<li>E-4031<sup>†</sup></li>
<li><a href="Ibutilide.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibutilide" title="Ibutilide">Ibutilide</a></li>
<li>Nifekalant</li>
<li><a href="Sotalol.htm" tppabs="https://ptable.com/wiki/compounds/A/Sotalol" title="Sotalol">Sotalol</a></li>
<li>Tedisamil</li>
<li>Vernakalant</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">class IV<br>(Phase 4→, Ca<sup>2+</sup> channel blockers)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Diltiazem.htm" tppabs="https://ptable.com/wiki/compounds/A/Diltiazem" title="Diltiazem">Diltiazem</a></li>
<li><a href="Verapamil.htm" tppabs="https://ptable.com/wiki/compounds/A/Verapamil" title="Verapamil">Verapamil</a><sup>#</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Receptor agonists<br>and antagonists</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">class II<br>(Phase 4→, β blockers)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Nadolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Nadolol" title="Nadolol">Nadolol</a></li>
<li><a href="Pindolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Pindolol" title="Pindolol">Pindolol</a></li>
<li><a href="Propranolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Propranolol" title="Propranolol">Propranolol</a></li>
<li><i>cardioselective</i>
<ul><li><a href="Acebutolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Acebutolol" title="Acebutolol">Acebutolol</a></li>
<li><a href="Atenolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Atenolol" title="Atenolol">Atenolol</a></li>
<li><a href="Esmolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Esmolol" title="Esmolol">Esmolol</a></li>
<li><a href="Metoprolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Metoprolol" title="Metoprolol">Metoprolol</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">A<sub>1</sub> agonist</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Adenosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Adenosine" title="Adenosine">Adenosine</a></li>
<li>Benzodiazepines</li>
<li><a href="Barbiturate.htm" tppabs="https://ptable.com/wiki/compounds/A/Barbiturate" title="Barbiturate">Barbiturates</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">M<sub>2</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>muscarinic antagonist: <a href="Atropine.htm" tppabs="https://ptable.com/wiki/compounds/A/Atropine" title="Atropine">Atropine</a></li>
<li><a href="Disopyramide.htm" tppabs="https://ptable.com/wiki/compounds/A/Disopyramide" title="Disopyramide">Disopyramide</a></li>
<li><a href="Quinidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinidine" title="Quinidine">Quinidine</a><br>muscarinic agonist: <a href="Digoxin.htm" tppabs="https://ptable.com/wiki/compounds/A/Digoxin" title="Digoxin">Digoxin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">α receptors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amiodarone.htm" tppabs="https://ptable.com/wiki/compounds/A/Amiodarone" title="Amiodarone">Amiodarone</a></li>
<li><a href="Bretylium.htm" tppabs="https://ptable.com/wiki/compounds/A/Bretylium" title="Bretylium">Bretylium</a></li>
<li><a href="Quinidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinidine" title="Quinidine">Quinidine</a></li>
<li><a href="Verapamil.htm" tppabs="https://ptable.com/wiki/compounds/A/Verapamil" title="Verapamil">Verapamil</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Ion transporters</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Na+/_K+-ATPase" scope="row" class="navbox-group" style="width:1%">Na<sup>+</sup>/ K<sup>+</sup>-ATPase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Digitoxin.htm" tppabs="https://ptable.com/wiki/compounds/A/Digitoxin" title="Digitoxin">Digitoxin</a></li>
<li><a href="Digoxin.htm" tppabs="https://ptable.com/wiki/compounds/A/Digoxin" title="Digoxin">Digoxin</a></li>
<li><a href="Ouabain.htm" tppabs="https://ptable.com/wiki/compounds/A/Ouabain" title="Ouabain">Ouabain</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>




<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-06-19" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Disopyramide&oldid=963436715  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Disopyramide&oldid=963436715'" tppabs="https://en.wikipedia.org/wiki/?title=Disopyramide&oldid=963436715">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>